PhaseBio Pharmaceuticals

IPO

Home | PhaseBio

Public · Malvern, United States · Founded 2002 · $2.8M raised

Employees
51–200
Founded
2002
Business Model
B2B
Total Funding
$2.8M
Last Round
Series DSep 2018
Rounds
6
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 7 funding rounds and 9 investors for this company. The full record is or through the API.

About

PhaseBio Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing novel therapies for serious cardiovascular diseases. The company's lead program was a ticagrelor reversal agent leveraging its proprietary ELP (elastin-like polypeptide) drug delivery platform. PhaseBio filed for Chapter 11 bankruptcy protection in October 2022 after its lead cardiovascular drug candidate failed to meet its primary endpoint in a pivotal clinical trial.

Summary

PhaseBio Pharmaceuticals is a Biotech company based in Malvern, United States, founded in 2002. It has raised $2.8M in total across 6 rounds, most recently a Series D round in Sep 2018. Investors include New Enterprise Associates, AstraZeneca and Hatteras Venture Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

IPOOct 2018

Sign up to see all 7 events

Funding: Seed through Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Enveda

Enveda reads and translates nature’s hidden chemistry to accelerate the discovery of better medic...

Boulder, United States201–500Biotech, Artificial Intelligence
Series ETotal funding$1.1BSep 2026
Eikon TherapeuticsIPO

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...

Hayward, United States201–500Artificial Intelligence, Biotech
Series DTotal funding$1.1BFeb 2025
Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...

South San Francisco, United States51–200Artificial Intelligence, Biotech
Series ATotal funding$1.0BApr 2024
Treeline Biosciences

Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...

Watertown, United States51–200Biotech, Drug Discovery
Extension RoundTotal funding$821.8MSep 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

PhaseBio Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/phasebio-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/phasebio-pharmaceuticals" alt="PhaseBio Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>